Patients completed a 3-month loading phase with monthly intravitreal injections of 0.5 mg ranibizumab , followed by a 12-month maintenance phase during which investigators documented VA , additional injections , metamorphopsias , routine ophthalmological examinations and adverse events at monthly follow-up visits .